A higher incidence and severity of CIP have been observed with anti-PD-1 therapy than PD-L1 inhibitors in patients with NSCLC, suggesting that the mechanisms of CIP induced by the two agents are not completely the same (28). The gene discussed is CD274; the disease is hereditary sensory and autonomic neuropathy.